FrancophonIA/ELRC3.0 huggingface dataset:
English: Rare (may affect up to 1 in 1,000 people): inflammation of the colon, small intestine, which could be fatal (frequency not known);
Estonian: • põletik käärsooles, peensooles, mis võib lõppeda surmaga (sagedus teadmata); soole mulgustumine (perforatsioon).
English: Tabulated list of adverse reactions in gastric adenocarcinoma cancer for Taxespira 75 mg/m² in combination with cisplatin and 5-fluorouracil
Estonian: Kõrvaltoimete tabel mao adenokartsinoomi kombinatsioonravi korral Taxespira'ga annuses 75 mg/m kombinatsioonis tsisplatiini ja 5-fluorouratsiiliga
English: EU/1/15/1017/003 120 mg/6 ml vial x 1 vial
Estonian: EU/1/15/1017/003 120 mg/6 ml viaal x 1 viaal
English: Each ml of solution contains 20 mg of docetaxel (as trihydrate).
Estonian: 20 mg dotsetakseeli (trihüdraadina).
English: Description of selected adverse reactions in breast cancer for Taxespira 100 mg/m 2 in combination with trastuzumab
Estonian: Rinnanäärmevähi kõrvaltoimete valikuline kirjeldus Taxespira'ga annuses 100 mg/m² ja trastuzumabiga
English: • Docetaxel 30 mg/m2 administered weekly for the first 5 weeks in a 6 week cycle for 5 cycles.
Estonian: 100 mg/m 2 1. päeval, tsüklit korrati iga 4 nädala järel (VCis).
English: In GEICAM 9805 study alopecia that started during the treatment period and persisted into the followup period was observed to be ongoing in 49 patients (9.2 %) in TAC arm and 35 patients (6.7 %) in FAC arm. Alopecia related to study drug started or worsened during the follow-up period in 42 patients (7.9 %) in TAC arm and 30 patients (5.8 %) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), alopecia was observed to be ongoing in 3 patients (0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.
Estonian: GEICAM 9805 uuringus püsis raviperioodil alanud alopeetsia järelkontrolliperioodini ning selle jätkumist täheldati 49 patsiendil (9,2%) TAC rühmas ja 35 patsiendil (6,7%) FAC rühmas.
English: • haemorrhage (bleeding)
Estonian: Veevaba sidrunhape (pH kohandamiseks)
English: EU/1/15/1017/004 140 mg/7 ml vial x 1 vial
Estonian: EU/1/15/1017/001 140 mg/7 ml viaal x 1 viaal
English: General disorders and administration site conditions In study TAX316, peripheral oedema that started during the treatment period and persisted into the follow-up period after the end of chemotherapy was observed in 119 of 744 TAC patients (16.0%) and 23 of 736 FAC patients (3.1%).
Estonian: TAX 316 uuringus teatati perifeersest tursest, mis algas raviperioodil ja püsis järelkontrolliperioodini pärast keemiaravi lõppu, TAC rühmas 119 patsiendil 744-st (16,0%)ja FAC rühmas 23 patsiendil 736st (3,1%).
English: Tabulated list of adverse reactions in head and neck cancer for Taxespira 75 mg/m² in combination with cisplatin and 5-fluorouracil
Estonian: Kõrvaltoimete tabel pea- ja kaelapiirkonna vähi kombinatsioonravi korral Taxespira'ga annuses 75 mg/m2 ning tsisplatiini ja 5-fluorouratsiiliga
English: EU/1/15/1017/005 160 mg/8 ml vial x 1 vial
Estonian: EU/1/15/1017/001 160 mg/8 ml viaal x 1 viaal
English: Lymphoedema (G3/4:
Estonian: Lümfiturse (G3./4.
English: Tabulated list of adverse reactions in non-small cell lung cancer for Taxespira 75 mg/m² in combination with cisplatin
Estonian: Kõrvaltoimete tabel mitteväikerakk-kopsuvähi kombinatsioonravi korral Taxespira'ga annuses 75 mg/m2 ja tsisplatiiniga
English: EU/1/15/1017/001 20 mg/1 ml vial x 1 vial
Estonian: EU/1/15/1017/001 20 mg/1 ml viaal x 1 viaal
English: Venous disorder (G3/4:
Estonian: Venoossed häired (G3./4.
English: EU/1/15/1017/002 80 mg/4 ml vial x 1 vial
Estonian: EU/1/15/1017/002 80 mg/4 ml viaal x 1 viaal
English: Metabolism and nutrition disorders Nervous system disorders
Estonian: Ainevahetus- ja toitumishäired Anoreksia Psühhiaatrilised häired
English: Amenorrhea was observed to be ongoing at the end of the follow-up period (median follow-up time of 8 years) in 121 patients of 744 TAC patients (16.3 %) and 86 FAC patients
Estonian: Järelkontrolliperioodi lõpus (järelkontrolli mediaankestus 8 aastat), täheldati selle jätkumist TAC rühmas 121 patsiendil 744-st (16,3%) ja FAC rühmas 86 patsiendil 736-st (11,7%).
English: Taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
Estonian: Taxespira kombinatsioonis kapetsitabiiniga on näidustatud lokaalselt levinud või metastaatilise rinnanäärmevähi raviks patsientidel, kellel eelnev tsütotoksiline keemiaravi on ebaõnnestunud.
English: Tabulated list of adverse reactions in breast cancer for Taxespira 100 mg/m² single agent
Estonian: Kõrvaltoimete tabel rinnanäärmevähi monoteraapia korral Taxespira'ga annuses 100 mg/m
English: Tabulated list of adverse reactions in breast cancer for Taxespira 100 mg/m² in combination with trastuzumab
Estonian: Kõrvaltoimete tabel rinnanäärmevähi kombinatsioonravi korral Taxespira'ga annuses 100 mg/m 2 ja trastuzumabiga
English: 6 hours when stored below 25°C.
Estonian: infusioonina manustamise aeg, temperatuuril kuni 25 °C.
English: • allergic reactions as described above
Estonian: Kui patsiendil eelpool mainitud reaktsioonid jätkuvad annusega
English: Hazard ratio: (95% CI) *p-value
Estonian: Riskide suhe: (95% CI) *p-väärtus
English: Weight increased
Estonian: astme AST tõus
English: Tabulated list of adverse reactions in breast cancer for Taxespira 75 mg/m² in combination with doxorubicin
Estonian: Kõrvaltoimete tabel rinnanäärmevähi kombinatsioonravi korral Taxespira'ga annuses 75 mg/m 2 ja doksorubitsiiniga
English: Docetaxel in combination with trastuzumab was studied for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2, and who previously had not received chemotherapy for metastatic disease.
Estonian: Dotsetakseeli ja trastuzumabi kombinatsioonravi uuriti varasemalt keemiaravi mittesaanud HER2-üleekspressiooniga metastaatilise rinnanäärmevähiga patsientidel.
English: Myocardial ischemia (G3/4:1.7%)
Estonian: Müokardi isheemia (G3./4.
English: IV
Estonian: LV
English: DO NOT use other docetaxel medicinal products consisting of 2 vials (concentrate and solvent) with this medicinal product (Taxespira 140 mg/7 ml concentrate for solution for infusion, which contains only 1 vial).
Estonian: ÄRGE KASUTAGE koos selle ravimiga (Taxespira 140 mg/7 ml infusioonilahuse kontsentraat, mille pakend sisaldab ainult1 viaali) teisi dotsetakseeli sisaldavaid ravimpreparaate, mille pakendis on 2 viaali (kontsentraat ja lahusti).
English: • heart failure
Estonian: Südame häired
English: • If you get any side effects talk to your doctor, hospital pharmacist or nurse.
Estonian: - Kui teil tekib ükskõik milline kõrvaltoime, pidage nõu oma arsti, haiglaapteekri või meditsiiniõega.
English: Vial label
Estonian: Vedelikupeetus
English: (750 mg/m2 per day for 5 days) or cisplatin (100 mg/m2 on day 1) and 5-fluorouracil (1000 mg/m2 per day for 5 days).
Estonian: Võrdlushaara patsiendid said tsisplatiini (P) 100 mg/m2 ja seejärel 5-fluorouratsiili (F) 1000 mg/m2 päevas 5 päeva (PF).
English: Taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.
Estonian: Taxespira on näidustatud lokaalselt levinud või metastaatilise rinnanäärmevähi monoteraapiaks patsientidel, kellel eelnev tsütotoksiline ravi on ebaõnnestunud.
English: In the pivotal SCCHN studies patients who experienced complicated neutropenia (including prolonged neutropenia, febrile neutropenia, or infection), it was recommended to use G-CSF to provide prophylactic coverage (e.g., day 6-15) in all subsequent cycles.
Estonian: kauakestev neutropeenia, febriilne neutropeenia või infektsioon), kasutada G-CSF-i profülaktiliseks kaitseks (nt 6.
English: Ventricular arrhythmia including ventricular tachycardia (frequency not known), sometimes fatal, has been reported in patients treated with docetaxel in combination regimens including doxorubicin, 5fluorouracil and/ or cyclophosphamide.
Estonian: Patsientidel, keda on ravitud dotsetakseeliga osana kombinatsioonravist, mis sisaldab doksorubitsiini, 5-fluorouratsiili ja/või tsüklofosfamiidi, on teatatud ventrikulaarsest arütmiast, sh ventrikulaarsest tahhükardiast (esinemissagedus teadmata), mis mõnikord lõppesid surmaga.
English: Dyspepsia (G3/4:
Estonian: Düsgeusia (G3./4.
English: DO NOT use other docetaxel medicinal products consisting of 2 vials (concentrate and solvent) with this medicinal product (Taxespira 20 mg/1 ml concentrate for solution for infusion, which contains only 1 vial).
Estonian: ÄRGE KASUTAGE koos selle ravimiga (Taxespira 20 mg/1 ml infusioonilahuse kontsentraat, mille pakend sisaldab ainult 1 viaali) teisi dotsetakseeli sisaldavaid ravimpreparaate, mille pakendis on 2 viaali (kontsentraat ja lahusti).
English: Full analysis set (intent-to-treat)
Estonian: Kaasatud kõik patsiendid ravikavatsuse alusel (intent-to-treat) Hinnanguline keskmine elulemus (Estimated median survival)
English: DO NOT use other docetaxel medicinal products consisting of 2 vials (concentrate and solvent) with this medicinal product (Taxespira 120 mg/6 ml concentrate for solution for infusion, which contains only 1 vial).
Estonian: ÄRGE KASUTAGE koos selle ravimiga (Taxespira 120 mg/6 ml infusioonilahuse kontsentraat, mille pakend sisaldab ainult1 viaali) teisi dotsetakseeli sisaldavaid ravimpreparaate, mille pakendis on 2 viaali (kontsentraat ja lahusti).
English: Disease free survival
Estonian: Haigusvaba elulemus Riskide suhe*
English: Cancer pain (G3/4:
Estonian: Kasvaja valu (G3./4.
English: DO NOT use other docetaxel medicinal products consisting of 2 vials (concentrate and solvent) with this medicinal product (Taxespira 160 mg/8 ml concentrate for solution for infusion, which contains only 1 vial).
Estonian: ÄRGE KASUTAGE koos selle ravimiga (Taxespira 160 mg/8 ml infusioonilahuse kontsentraat, mille pakend sisaldab ainult 1 viaali) teisi dotsetakseeli sisaldavaid ravimpreparaate, mille pakendis on 2 viaali (kontsentraat ja lahusti).
English: Number of patients Median survival (months) 95% CI
Estonian: Elulemuse mediaan (kuud) 95% CI
English: Infections (G3/4: 5%)
Estonian: Infektsioonid (G3./4.
English: In this study, 255 patients were randomised to treatment with docetaxel (75 mg/m2 as a 1 hour intravenous infusion every
Estonian: Uuringusse randomiseeritud 255 patsienti said ravi dotsetakseeli (75 mg/m2 ühetunnine intravenoosne infusioon iga 3 nädala järel) ja kapetsitabiiniga (1250 mg/m2 kaks korda päevas 2 nädala jooksul, millele järgnes 1-nädalane paus).
English: Immune system disorders Metabolism and nutrition disorders Nervous system disorders
Estonian: MedDRA organsüsteemi klass Väga sagedased kõrvaltoimed Sagedased kõrvaltoimed Närvisüsteemi häired
English: Taxespira 120 mg/6 ml concentrate for solution for infusion.
Estonian: Taxespira 120 mg/6 ml infusioonilahuse kontsentraat Docetaxelum i.v.
English: DO NOT use other docetaxel medicinal products consisting of 2 vials (concentrate and solvent) with this medicinal product (Taxespira 80 mg/4 ml concentrate for solution for infusion, which contains only 1 vial).
Estonian: ÄRGE KASUTAGE koos selle ravimiga (Taxespira 80 mg/4 ml infusioonilahuse kontsentraat, mille pakend sisaldab ainult1 viaali) teisi dotsetakseeli sisaldavaid ravimpreparaate, mille pakendis on 2 viaali (kontsentraat ja lahusti).
English: Elderly people
Estonian: Lapsed ja noorukid
English: Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
Estonian: Taxespira kombinatsioonis tsisplatiini ja 5-fluorouratsiiliga on näidustatud mao metastaatilise adenokartsinoomi, k.a.
English: In study GEICAM 9805 peripheral oedema that started during the treatment period persisted into the follow-up period in 4 patients (0.8%) in TAC arm and in 2 patients (0.4%) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), no patients (0%) in TAC arm had peripheral oedema and it was observed to be ongoing in 1 patient (0.2%) in FAC arm. Lymphoedema that started during the treatment period persisted into the follow-up period in 5 patients (0.9%) in TAC arm and 2 patients (0.4 %) in FAC arm. At the end of the follow-up period, lymphoedema was observed to be ongoing in 4 patients (0.8%) in TAC arm, and in 1 patient (0.2%) in FAC arm.
Estonian: Opereeritava lümfisõlm-siiretega rinnanäärmevähiga patsiendid (TAX 316) Paljukeskuselise avatud randomiseeritud uuringu andmed toetavad dotsetakseeli kasutamist opereeritava lümfisõlm-siiretega rinnanäärmevähi adjuvantraviks patsientidel, kelle KPS ≥ 80% ja vanus on 18…70 a. Pärast patsientide jaotust lümfisõlmede haaratuse alusel (1…3, 4+), jagati 1491 patsienti juhuvaliku käigus 2 ravihaara: TAC ravihaar, kellele manustati dotsetakseeli 75 mg/m 1 tund pärast doksorubitsiini annuses 50 mg/m2 ja tsüklofosfamiidi annuses 500 mg/m2, või FAC
English: Nausea (G3/4: 5%); Stomatitis (G3/4:
Estonian: aste: 4%); Kõhukinnisus (G3./4.
English: Tabulated list of adverse reactions in breast cancer for Taxespira 75 mg/m² in combination with capecitabine
Estonian: Kõrvaltoimete tabel rinnanäärmevähi kombinatsioonravi korral Taxespira'ga annuses 75 mg/m 2 ja kapetsitabiiniga
English: Vomiting (G3/4: 4.2%); Diarrhoea (G3/4: 3.4%); Constipation (G3/4:
Estonian: aste: 23,7%); Oksendamine (G3./4.
English: Description of selected adverse reactions in breast cancer for Taxespira 100 mg/m 2 single agent
Estonian: Rinnanäärmevähi kõrvaltoimete valikuline kirjeldus Taxespira 100 mg/m² monoteraapia korral
English: Adjusted hazard ratio (95% CI) *p-value
Estonian: Kohandatud riskide suhe (95% CI) *p-väärtus
English: Hypersensitivity reactions (frequency not known) have been reported with docetaxel in patients who previously experienced hypersensitivity reactions to paclitaxel.
Estonian: Patsientidel, kellel on olnud ülitundlikkusreaktsioone paklitakseelile, on teatatud ülitundlikkusreaktsioonidest dotsetakseelile (esinemissagedus teadmata).
English: G3/4 Blood bilirubin increased (<5%); G3/4 Blood alkaline phosphatase increased (<4%); G3/4 AST increased (<3%); G3/4 ALT increased (<2%)
Estonian: astme bilirubiinisisalduse tõus veres (< 2,5%); 3./4.
English: Taxespira 140 mg/7 ml concentrate for solution for infusion.
Estonian: Taxespira 140 mg/7 ml infusioonilahuse kontsentraat Docetaxelum
English: Taxespira 160 mg/8 ml concentrate for solution for infusion.
Estonian: Taxespira 160 mg/8 ml infusioonilahuse kontsentraat Docetaxelum i.v.
English: All patients on the docetaxel-containing arm of the study received prophylactic antibiotics.
Estonian: Haiguse algkolde ja/või kaela kirurgilist resektsiooni võis teha igal ajal pärast KRT-d. Kõik dotsetakseeli sisaldava haara patsiendid said profülaktiliselt antibiootikume.
English: Dehydration (G3/4: 2%)
Estonian: Dehüdratsioon (G3./4.
English: Paediatric population
Estonian: Neerukahjustusega patsiendid
English: Infusion site reaction;
Estonian: Infusioonilahuse kontsentraat.
English: • decrease of the sodium, potassium, magnesium, and/or calcium in your blood (electrolyte balance disorders).
Estonian: - pneumoonia (kopsupõletik) - kopsufibroos (kopsukoe armistumine ja tihkestumine koos õhupuudusega) - hägune nägemine, mis on tingitud reetina tursest silmas (tsüstiline maakula ödeem) - naatriumi, kaaliumi, magneesiumi ja/või kaltsiumi sisalduse vähenemine teie veres
English: Cardiac left ventricular function decrease (G3/4:
Estonian: Vasaku vatsakese funktsiooni langus (G3./4.
English: What Taxespira looks like and contents of the pack
Estonian: RAVIMVORM JA PAKENDI SUURUS
English: Fever (G3/4: 1.2%)
Estonian: aste: 1,2%)
English: The concentrate is a pale yellow to brownish-yellow solution.
Estonian: Kontsentraat on kahvatukollane kuni pruunikaskollane lahus.
English: In this case close monitoring is required.
Estonian: Antud juhul on vajalik hoolikas jälgimine.
English: (Study conducted in 8 patients)
Estonian: (Uuring läbi viidud 8 patsiendil)
English: However, the number of abortions increased.
Estonian: Samas suurenes abortide arv.
English: (Possible mechanism)
Estonian: (Võimalik mehhanism)
English: The reason for this is not known.
Estonian: Selle põhjus on teadmata.
English: Use with caution.
Estonian: Kasutada ettevaatlikult.
English: Mechanism unknown.
Estonian: Mehhanism teadmata.
English: Look out for important symptoms
Estonian: Pidage silmas tähtsaid sümptomeid
English: You need to keep taking it every day to stop your illness getting worse.
Estonian: Te peate seda võtma iga päev, et takistada haiguse süvenemist.
English: • if they drink alcohol
Estonian: • kui tarvitatakse alkoholi
English: • if their immune systems are very weak
Estonian: • kui immuunsüsteem on väga nõrk
English: GSS was derived using ANRS 2007 guidelines.
Estonian: GSS tuletati ANRS 2007 juhiseid kasutades.
English: Stay in regular contact with your doctor
Estonian: Olge regulaarselt ühenduses oma arstiga
English: → Don't drive or operate machinery unless you're feeling well.
Estonian:  Ärge juhtige autot ega töötage masinatega, kui te ei tunne ennast hästi.
English: • If you are taking any other medicines.
Estonian: • Kui te võtate ükskõik milliseid teisi ravimeid.
English: Protect other people.
Estonian: Kaitske teisi inimesi.
English: This reaction may be delayed.
Estonian: See reaktsioon võib olla hilise tekkega.
English: These ingredients may cause allergic reactions (sometimes delayed).
Estonian: Need koostisained võivad põhjustada allergilisi reaktsioone (mõnikord hilist tüüpi).
English: Repeat steps 4 to 8 in the same way until you have taken the whole dose.
Estonian: Korrake punkte 4-8, kuni olete manustanud kogu täisannuse.
English: For this reason, it is very important to talk to your doctor about any changes in your health.
Estonian: Seetõttu on väga tähtis, et te informeeriksite arsti kõigist oma tervisliku seisundi muutustest.
English: All Patients, RD=F Analysis2
Estonian: Kõik patsiendid, RD=F analüüs2
English: To avoid this happening, and to stop your illness getting worse, it is very important that you keep taking all your medicines exactly as prescribed.
Estonian: Selle vältimiseks ning haiguse süvenemise peatamiseks on väga tähtis võtta kõiki ravimeid täpselt ettekirjutuste järgi.
English: You may also be allergic to Telzir.
Estonian: Te võite olla allergiline ka Telzir'i suhtes.
English: Avenida de Extremadura 3 09400 Aranda de Duero Burgos Spain
Estonian: Avenida de Extremadura 3 09400 Aranda de Duero Burgos Hispaania
English: Therefore, no recommendations can be made in this patient population.
Estonian: Seetõttu ei saa anda soovitusi nendele patsientidele.
English: Like all medicines, this medicine can cause side effects, but not everyone gets them.
Estonian: Nagu kõik ravimid, võib ka see ravim põhjustada kõrvaltoimeid, kuigi kõigil neid ei teki.
English: If this happens, Telzir must be stopped immediately and you must never take it again.
Estonian: Sellisel juhul tuleb Telzir'i võtmine otsekohe lõpetada ning seda ei tohi enam kunagi uuesti kasutada.
English: These products may cause an allergic reaction in some individuals.
Estonian: Need ained võivad mõnel inimesel põhjustada allergilist reaktsiooni.
English: Date of renewal of authorisation: 15 May 2009.
Estonian: Müügiloa uuendamise kuupäev: 15. mai 2009
English: Do not take Telzir:
Estonian: Ärge võtke Telzir'i:
English: Swallow the tablets whole, with some water or another drink.
Estonian: Neelake tabletid tervelt koos vee või mõne muu joogiga.
English: Other medicines and Telzir
Estonian: Muud ravimid ja Telzir
English: Week 144
Estonian: 144. nädal
English: People may be more likely to get this condition:
Estonian: See haigus võib tekkida suurema tõenäosusega juhul:
English: You may still develop other infections and illnesses linked to HIV infection.
Estonian: Teil võivad sellele vaatamata tekkida teised HIV-infektsiooniga seotud nakkused ja haigused.
English: Tell your doctor or pharmacist if you're taking or have recently taken any other medicinesthese include herbal medicines or other medicines you bought without a prescription.
Estonian: Teatage oma arstile või apteekrile, kui te kasutate või olete hiljuti kasutanud mis tahes muid ravimeid - siia kuuluvad ka taimsed ravimid või ilma retseptita ostetud ravimid.
English: • If you have a known allergy to medicines containing sulphonamide.
Estonian: • Kui teil on teadaolev allergia sulfoonamiidi sisaldavate ravimite suhtes.
English: In view of the low exposure in reproductive toxicity studies, the potential developmental toxicity of Telzir has not been fully determined.
Estonian: Arvestades madalat ekspositsiooni reproduktsioonitoksilisuse uuringutes, ei ole Telzir'i potentsiaalne arengutoksilisus täielikult kindlaks tehtud.
English: These symptoms are probably caused by the body's immune system becoming stronger, so that the body starts to fight these infections.
Estonian: Need sümptomid on arvatavasti tingitud organismi immuunvastuse paranemisest, mistõttu hakkab organism nende infektsioonide vastu võitlema.
English: All Patients CD4-count <50
Estonian: Kõik patsiendid CD4-arv <50
English: The use of higher ritonavir doses might alter the safety profile of the combination and therefore is not recommended.
Estonian: Suuremate ritonaviiriannuste kasutamine võib muuta selle kombinatsiooni ohutusprofiili, mistõttu seda ei soovitata.
English: HIV can become resistant to anti-HIV medicines.
Estonian: HIV võib muutuda resistentseks HIV-vastaste ravimite suhtes.
English: (Read the package leaflet of Telzir oral suspension for guidance on whether to take it with or without food.)
Estonian: (Lugege Telzir'i suukaudse suspensiooni pakendi infolehest juhiseid selle kohta, kas võtta seda koos toiduga või ilma).
English: Do not leave the syringe in the bottle.
Estonian: Ärge jätke süstalt pudelisse.
English: Study performed with amprenavir.
Estonian: Amprenaviiriga läbi viidud uuring.
English: Adverse reactions are listed by MedDRA system organ class and absolute frequency.
Estonian: Kõrvaltoimed on loetletud MedDRA organsüsteemi klassi ja absoluutse esinemissageduse järgi.
English: Hertfordshire SG12 0DJ United Kingdom
Estonian: Hertfordshire SG12 0DJ Ühendkuningriik
English: Patients with renal impairment have not been specifically studied.
Estonian: Neerukahjustusega patsiente ei ole eraldi uuritud.
English: Overall the safety profile in these 158 children and adolescents was similar to that observed in the adult population.
Estonian: Üldiselt olid nimetatud 158 lapsel ja noorukil täheldatud kõrvaltoimed sarnased täiskasvanute omadega.
English: This is very important, as Telzir or ritonavir can strengthen or weaken the effects of other medicines.
Estonian: See on väga tähtis, kuna Telzir ja ritonaviir võivad viia teiste ravimite toime tugevnemise või nõrgenemiseni.
English: See section ‘Other medicines and Telzir'.
Estonian: Vt lõik „Muud ravimid ja Telzir“.
English: Following administration of Telzir, the half-life of amprenavir is 7.7 hours.
Estonian: Pärast Telzir'i manustamist on amprenaviiri poolväärtusaeg 7,7 tundi.
English: • methadone (a heroin substitute)
Estonian: • metadoon (heroiini asendusaine)
English: • fluticasone propionate and similar medicines used to treat asthma, unless considered essential.
Estonian: • flutikasoonpropionaat ja sarnased ravimid, mida kasutatakse astma raviks, kui see ei ole hädavajalik.
English: Resistance patterns were similar to those observed in adults.
Estonian: Resistentsuse mudelid olid sarnased täiskasvanutel täheldatuga.
English: Vistor hf.
Estonian: Ísland Vistor hf.
English: Data from this small number further analysed by GSS subgroups need to be interpreted with caution.
Estonian: Sellest väikesest alagrupist saadud andmeid, mida analüüsiti edasi GSS alagruppide alusel, tuleb interpreteerida ettevaatusega.
English: It is therefore important that you carefully read the package leaflet provided with these medicines.
Estonian: Seetõttu on tähtis hoolega läbi lugeda kõigi nende ravimite pakendi infolehed.